Sable Bio

Sable Bio builds an artificial intelligence platform for pharmaceutical drug safety assessment.

London, UK—Founded 2023—Website

£4.3MTotal raised

Sable Bio develops an artificial intelligence platform designed to help pharmaceutical companies identify safety risks early in the drug discovery process. The London-based startup provides predictive insights to reduce the risk of clinical trial failures.

Founders

Josh Almond-Thynne

co-founder and CEO

Josh brings scientific and operating experience, having previously worked as a principal scientist at BenevolentAI before co-founding Sable Bio.

Investors

Seed11 February 2026
£2.8M
MMCLead
Episode 1Follow-on
SeedcampFollow-on
Pre-Seed6 February 2024
£1.5M
Episode 1Lead
Seedcamp
FA
Finster AI

Funding history

Seed11 February 2026

£2.8M

Sable Bio secures £2.8m in seed funding from MMC Ventures to scale its drug safety platform.

The seed round was led by MMC Ventures with participation from Episode 1 Ventures and Seedcamp to fund team expansion and product development.

Pre-Seed6 February 2024

£1.5M

Sable Bio secures £1.5m in pre seed funding led by Episode 1 Ventures to scale its drug safety platform.

The pre seed round was led by Episode 1 Ventures and will support infrastructure development and team expansion.